Telix Pharmaceuticals Limited
TLX
$9.08
-$0.28-2.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.10M | 19.84M | 32.81M | 32.57M | 32.18M |
| Total Depreciation and Amortization | 12.44M | 9.24M | 5.28M | 5.03M | 4.75M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 39.29M | 44.55M | 30.27M | 22.91M | 15.18M |
| Change in Net Operating Assets | -42.47M | -42.47M | -42.47M | -32.45M | -21.89M |
| Cash from Operations | 20.36M | 31.16M | 25.89M | 28.06M | 30.22M |
| Capital Expenditure | -13.03M | -11.18M | -9.41M | -8.45M | -7.40M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -237.25M | -137.98M | -23.14M | -19.93M | -16.62M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -67.61M | -63.79M | -56.83M | -39.26M | -21.09M |
| Cash from Investing | -317.89M | -212.95M | -89.38M | -67.64M | -45.11M |
| Total Debt Issued | 653.24M | 654.23M | 655.43M | 330.44M | 5.46M |
| Total Debt Repaid | -5.55M | -4.54M | -2.74M | -2.52M | -2.30M |
| Issuance of Common Stock | 1.04M | 1.01M | 839.20K | 2.52M | 4.20M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -14.88M | -13.00M | -15.82M | -8.38M | -940.20K |
| Cash from Financing | 417.88M | 421.74M | 422.24M | 216.55M | 5.02M |
| Foreign Exchange rate Adjustments | 37.70M | 29.58M | 26.87M | 13.14M | -954.80K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 158.05M | 269.54M | 385.61M | 190.12M | -10.83M |